# Atherectomy Devices Market

> Atherectomy Devices Market Research Report by Product Type (Directional Atherectomy Systems, Orbital Atherectomy Systems, and others), by Application (Cardiovascular, Neurovascular, Peripheral Vascular, and others), by End User Industry-Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 7.0%
- **2025:** USD 1.14 Billion
- **2035:** USD 2.24 Billion
- **Key Players:** Boston Scientific Corporation, Abbott Laboratories, Koninklijke Philips N.V., Medtronic plc, Cardinal Health (Cordis), Terumo Corporation, AngioDynamics, Inc., Avinger, Inc.

**Report ID:** MRFR/HC/5853-HCR · **Pages:** 160 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/atherectomy-devices-market-7322

---

## Market Summary

## Atherectomy Devices Market Summary

The Atherectomy Devices Market closed 2025 at USD 1.14 billion, enters the forecast window at USD 1.22 billion in 2026, and is projected to reach USD 2.24 billion by 2035 at a 7.0% CAGR. Two catalysts anchor that trajectory. The first is the U.S. Centers for Medicare & Medicaid Services' decision to keep office-based lab payment for lower-extremity revascularization intact under the 2025 Physician Fee Schedule, which preserved roughly USD 8,000–11,000 in facility-side reimbursement per peripheral case [[5]](https://cms.gov). The second is the sustained global rise in [peripheral artery disease](https://www.marketresearchfuture.com/reports/peripheral-artery-disease-market-1540), now affecting more than 230 million adults worldwide [[3]](https://healthdata.org).

Vessel preparation has changed shape. Balloon-only angioplasty, long the default for calcified femoropopliteal and below-the-knee lesions, is giving way to debulking-first strategies paired with drug-coated balloons — a sequence that clinical registries link to lower bailout stenting rates [[9]](https://scai.org). Manufacturers have spent accordingly: Abbott's USD 890 million acquisition of Cardiovascular Systems Inc. in 2023 remains the clearest signal of where capital is moving [[16]](https://abbott.com).

North America holds 52.5% of global revenue, supported by the deepest [interventional cardiology](https://www.marketresearchfuture.com/reports/interventional-cardiology-market-8735) infrastructure anywhere. Asia-Pacific grows fastest at a 9.4% CAGR through 2035. Europe, second at 24.0%, leans on Germany's ambulatory reform agenda. Consolidation should sharpen through 2030.

## Key Report Takeaways

### • By Product

- Rotational systems remain the volume anchor of the Atherectomy Devices Market, holding an estimated 34.5% revenue share in 2025
- Orbital platforms are the momentum story, expanding at an 8.6% CAGR across the forecast window
- Photo-ablative (laser) systems contributed roughly USD 0.21 billion in 2025 revenue

### • By Application

- Peripheral vascular procedures dominate the Atherectomy Devices Market with a 58.0% share of 2025 revenue
- Cardiovascular applications are forecast to compound at 6.6% annually to 2035
- Neurovascular use, still nascent, generated close to USD 0.05 billion in 2025

### • By Region

- North America accounts for 52.5% of global revenue
- Asia-Pacific posts the strongest regional CAGR at 9.4%
- Europe generated approximately USD 0.27 billion in 2025

## Market Size and Forecast (2021–2035)

Figures below blend hospital and ambulatory procedure volumes drawn from national discharge databases, device-level pricing captured through distributor channel checks across 19 countries, and reported segment revenue from publicly listed manufacturers. Historical years are reconciled against reimbursement claims data; forecast years apply procedure-growth elasticity against installed cath lab capacity.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising peripheral artery disease prevalence | +1.5 pp | Global | Long-term (≥4 yr) | [3] |
| Ambulatory and office-based lab migration | +1.2 pp | North America | Medium-term (2–4 yr) | [5] |
| Severe lesion calcification in aging cohorts | +1.0 pp | Europe, Japan | Long-term (≥4 yr) | [7] |
| Asia-Pacific cath lab infrastructure buildout | +0.9 pp | Asia-Pacific | Medium-term (2–4 yr) | [11] |
| Intravascular imaging-guided vessel prep | +0.8 pp | North America, Europe | Medium-term (2–4 yr) | [9] |
| Diabetes-driven below-the-knee disease burden | +0.7 pp | MEA, Asia-Pacific | Long-term (≥4 yr) | [4] |
| Combination therapy with drug-coated balloons | +0.6 pp | Global | Short-term (≤2 yr) | [13] |

### Peripheral Artery Disease Prevalence

Global burden estimates place peripheral artery disease at over 230 million adults, with incidence climbing fastest in low- and middle-income countries where diabetes prevalence has doubled since 2000 [[3]](https://healthdata.org). That epidemiology feeds directly into procedure volumes across the Atherectomy Devices Market. In the United States alone, roughly 400,000 lower-extremity revascularization procedures are performed annually, and calcified lesions — the primary indication for debulking — appear in an estimated 40% of them [[4]](https://ahajournals.org).

### Site-of-Service Migration

Payment policy has quietly rewritten procedure economics. Medicare's non-facility rates for peripheral interventions in office-based labs continue to exceed hospital outpatient equivalents for several codes, and roughly 26% of U.S. peripheral cases now occur outside hospital walls [[5]](https://cms.gov). Operators in these settings favor devices with short setup times and low capital overhead.

### Imaging-Guided Vessel Preparation

Intravascular ultrasound use in peripheral cases rose from under 10% to approximately 28% of U.S. procedures between 2019 and 2024 [[9]](https://scai.org). Better lesion characterization means fewer blind passes and more deliberate device selection — which favors specialized debulking rather than generic dilation.

### Asia-Pacific Capacity Expansion

China added more than 1,100 catheterization laboratories between 2020 and 2024 under successive national cardiovascular capacity programs, while India's PM-ABHIM allocation of roughly USD 8.4 billion has funded district-level cardiac facilities [[11]](https://nhc.gov.cn)[[12]](https://mohfw.gov.in).

## Restraints

## Restraints Impact Analysis

Restraint weightings reflect analyst assessment of drag on adoption velocity within the Atherectomy Devices Market. They are directional indicators, not deductions applied against the forecast CAGR.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Reimbursement scrutiny and utilization audits | −1.1 pp | United States | Short-term (≤2 yr) | [6] |
| Competition from intravascular lithotripsy | −1.0 pp | Global | Short-term (≤2 yr) | [13] |
| Distal embolization and perforation risk | −0.9 pp | Global | Medium-term (2–4 yr) | [15] |
| Per-procedure cost premium over balloon-only | −0.7 pp | Emerging markets | Long-term (≥4 yr) | [10] |
| EU MDR recertification burden | −0.5 pp | Europe | Medium-term (2–4 yr) | [8] |

### Reimbursement Scrutiny

Federal oversight has tightened. Office-based lab utilization patterns drew a formal HHS Office of Inspector General work-plan item in 2024, and several commercial payers introduced prior-authorization requirements for repeat peripheral interventions within 12 months [[6]](https://oig.hhs.gov). Providers facing audit exposure defer marginal cases.

### Modality Competition

Intravascular lithotripsy has taken a meaningful share of the calcified-lesion pool since 2021, aided by a shorter learning curve and a lower reported dissection rate. Analyst channel checks suggest lithotripsy captured roughly 18% of calcium-modification procedure volume by 2025 [[13]](https://crf.org).

### Procedural Risk Profile

Registry data continues to show distal embolization in 2–8% of cases depending on device class and lesion morphology, requiring embolic protection in many peripheral applications [[15]](https://jvascsurg.org). Each added component raises cost per case and lengthens procedure time.

## Opportunities

## Atherectomy Devices Market Opportunities

### Below-the-Knee Indication Expansion

Infrapopliteal disease remains underserved. Chronic limb-threatening ischemia carries a one-year major amputation risk near 20% without revascularization, yet dedicated below-the-knee debulking platforms are few [[4]](https://ahajournals.org). Manufacturers that secure specific labeling here gain a defensible niche.

### Emerging-Market Entry Through Value Engineering

A small portion of Western Europe's per-capita cath lab capacity serves over 2 billion people in India, Brazil, and Indonesia combined [[11]](https://nhc.gov.cn). Single-use, stripped-down platforms that are 40–50% less expensive than high-end Western systems have the potential to release volume that is currently foreclosed by pricing structures.

### Procedural Data Monetization

Modern consoles capture rotational speed, runtime, and pressure telemetry on every pass. Vendors are beginning to package anonymized procedural analytics as subscription services for hospital quality departments — recurring revenue layered atop a consumables business.

### Combination Therapy Bundles

Pairing debulking with drug-coated balloon delivery in a single commercial bundle simplifies purchasing and improves attach rates. Early bundling pilots in Germany and Japan show meaningfully higher per-case revenue capture [[13]](https://crf.org).

### Ambulatory Channel Specialization

Compared to hospital committees, office-based operators have quicker cycles, are more price sensitive, and do not have a capital budget. One underutilized avenue in the market for atherectomy devices is a dedicated ambulatory sales motion.

## Future Outlook

## Atherectomy Devices Market Future Outlook

### Algorithmic Procedure Guidance

Prototypes of console-embedded software that modifies ablation parameters or burr speed in response to real-time tissue feedback are being submitted. By early 2025, the FDA had approved more than 1,000 AI-enabled medical devices, most of which were in imaging-related categories, demonstrating regulators' willingness to participate [[17]](https://fda.gov). Before 2029, the first adaptive control features in the market for atherectomy devices should be approved.

### Consumable-Led Platform Economics

High-margin single-use catheters are increasingly being placed through capital consoles. Placement-plus-commitment contracts, which stabilize revenue and increase switching costs at the account level, are becoming more popular among vendors.

### Outcomes-Linked Purchasing

European and Japanese payers are experimenting with contracts tied to reintervention rates at 12 months. Manufacturers with strong registry evidence stand to benefit; those without will face price-only competition.

### Supply Chain Regionalization

Tariff exposure and post-pandemic resilience planning are pushing manufacturing closer to demand. Several suppliers to the Atherectomy Devices Market have announced Mexican and Malaysian capacity, and India's production-linked incentive scheme for medical devices has committed roughly USD 420 million toward domestic component manufacturing [[12]](https://mohfw.gov.in).

## Segment Insights

## Atherectomy Devices Market Segmentation

### By Product

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Rotational Atherectomy Systems | 34.5% share | Coronary calcified lesion standard of care |
| Orbital Atherectomy Systems | 8.6% CAGR | Bidirectional sanding, eccentric lesions |
| Directional Atherectomy Systems | USD 0.26 Billion | Tissue capture in femoropopliteal disease |
| Photo-Ablative (Laser) Atherectomy Systems | 18.5% share | In-stent restenosis, thrombotic lesions |

Rotational platforms retain primacy in the coronary space because two decades of trial evidence and operator familiarity are difficult to displace, and because severe coronary calcification appears in roughly 18–20% of percutaneous cases [[7]](https://acc.org). Orbital systems are gaining faster, particularly in peripheral work, where their bidirectional mechanism handles eccentric calcium that concentric burrs struggle with. Within the Atherectomy Devices Market, product choice is increasingly lesion-specific rather than institution-specific.

### By Application

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Peripheral Vascular Applications | 58.0% share | PAD prevalence, limb salvage imperatives |
| Cardiovascular Applications | 6.6% CAGR | Complex PCI in calcified anatomy |
| Neurovascular Applications | USD 0.05 Billion | Early-stage carotid and intracranial use |

Peripheral applications carry the Atherectomy Devices Market and will continue to. Lower-extremity disease produces long, heavily calcified lesions where balloon-only strategies deliver poor durability, and the amputation-avoidance argument gives clinicians latitude to escalate. Cardiovascular use grows more slowly but from a technically demanding base; lithotripsy competition is most intense here [[13]](https://crf.org).

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals and Surgical Centers | 61.5% share | Complex case referral, inpatient backup |
| Ambulatory Care Centers | 9.8% CAGR | Favorable non-facility reimbursement |
| Others | USD 0.08 Billion | Specialty vascular clinics, research sites |

Hospitals remain the default for high-risk anatomy where surgical backup matters. Ambulatory centres, though, are the growth engine of the Atherectomy Devices Market — they now perform roughly a quarter of U.S. peripheral interventions and buy on entirely different criteria [[5]](https://cms.gov).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 52.5% share | Ambulatory conversion, imaging integration |
| Europe | USD 0.27 Billion | MDR compliance, day-case reform |
| Asia-Pacific | 9.4% CAGR | Cath lab buildout, domestic manufacturing |
| South America | 7.6% CAGR | Private hospital investment |
| Middle East & Africa | USD 0.03 Billion | Diabetes care programs, medical tourism |
| Total | USD 1.14 Billion | — |

Regional performance in the Atherectomy Devices Market tracks reimbursement generosity far more closely than disease prevalence.

### North America

| Country | Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| US | 88.0% | Office-based lab reimbursement [5] |
| Canada | 8.5% | Provincial vascular program funding [18] |
| Mexico | 3.5% | Private-sector cardiology expansion [19] |

American demand rests on a payment architecture no other country replicates. Medicare covers roughly 62 million beneficiaries, and peripheral revascularization sits among the higher-reimbursed outpatient interventional categories [[5]](https://cms.gov). Canada's growth is slower and centrally budgeted; Ontario's vascular quality program has standardized referral pathways but constrains device choice through provincial procurement. Mexico's momentum comes from private hospital groups in Monterrey and Guadalajara serving cross-border patients.

### Europe

| Country | Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| Germany | 26.5% | DRG day-case reform [20] |
| UK | 16.0% | NHS vascular network consolidation [21] |
| France | 14.5% | Forfait innovation pathway [22] |
| Italy | 11.0% | Regional cardiology investment |
| Spain | 8.5% | Diabetic limb salvage programs |
| Nordic Countries | 7.0% | Registry-driven procurement |
| Russia | 6.0% | Domestic substitution policy |
| Rest of Europe | 10.5% | Central European capacity growth |

Germany anchors the region. Its 2024 hospital reform pushed a defined list of interventions toward ambulatory settings, and vascular procedures featured prominently [[20]](https://bundesgesundheitsministerium.de). The UK moved the other direction structurally, consolidating arterial work into fewer high-volume centres — good for standardization, slower for new device adoption. EU MDR recertification has meanwhile thinned the field of smaller suppliers [[8]](https://health.ec.europa.eu).

### Asia-Pacific

| Country | Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| China | 38.0% | Volume-based procurement, domestic supply [11] |
| Japan | 22.5% | Reimbursement for calcified lesion devices [23] |
| India | 15.0% | PM-ABHIM infrastructure funding [12] |
| South Korea | 9.5% | High interventional cardiology density |
| ASEAN | 8.0% | Private hospital network growth |
| Rest of Asia-Pacific | 7.0% | Medical tourism corridors |

Asia-Pacific is where the Atherectomy Devices Market changes character. China's centralized volume-based procurement has compressed prices on comparable interventional categories by 40–70%, forcing multinationals to defend margin through premium differentiation while domestic entrants scale [[11]](https://nhc.gov.cn). Japan behaves differently — its reimbursement system rewards documented clinical benefit, and functional reimbursement categories for calcium modification devices were expanded in the 2024 revision [[23]](https://mhlw.go.jp).

### South America

| Country | Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| Brazil | 58.0% | ANVISA approvals, private insurance growth [24] |
| Argentina | 17.5% | Urban cardiology concentration |
| Rest of South America | 24.5% | Chile and Colombia capacity additions |

Brazil dominates by scale. Supplementary health coverage reaches roughly 51 million Brazilians, and that privately insured pool drives nearly all premium device consumption [[24]](https://gov.br/ans). Currency volatility remains the principal commercial risk for importers.

### Middle East & Africa

| Country | Metric (Share of Region) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 31.0% | Vision 2030 health sector transformation [25] |
| UAE | 24.0% | Medical tourism and private hospitals |
| South Africa | 18.5% | Established private cardiology sector |
| Egypt | 11.5% | Universal health insurance rollout |
| Rest of MEA | 15.0% | Gulf and North African capacity growth |

Diabetes prevalence in Gulf states exceeds 16% of adults — among the highest globally — producing exactly the calcified, distal disease patterns that debulking addresses [[25]](https://moh.gov.sa). Saudi Arabia's health sector transformation has funded new cardiac centres in Riyadh and Jeddah, though specialist operator supply remains the binding constraint.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is moderate and loosening. Market Research Future estimates a Herfindahl-Hirschman Index near 1,150, with the top five suppliers holding a combined 61–66% of global revenue. Abbott's absorption of Cardiovascular Systems Inc. consolidated the orbital franchise, while Philips and Becton Dickinson defend adjacent positions through laser and mechanical platforms, respectively.

| Company | Est. Revenue Share Range | Key Offerings for Atherectomy Devices Market | Strategic Positioning |
| --- | --- | --- | --- |
| Boston Scientific Corporation | ~17–21% | Rotational coronary platforms, thrombectomy adjuncts | Broadest interventional portfolio; hospital-channel strength |
| Abbott Laboratories | ~14–18% | Orbital coronary and peripheral systems | Post-CSI integration; imaging-plus-device bundling |
| Koninklijke Philips N.V. | ~11–14% | Excimer laser ablation platforms | Laser leadership tied to IVUS installed base |
| Medtronic plc | ~8–11% | Directional and support catheter systems | Global reach; peripheral vascular breadth |
| Becton, Dickinson and Company | ~7–10% | Mechanical rotational and aspiration devices | Strong European peripheral franchise |
| Cardinal Health (Cordis) | ~5–7% | Peripheral vascular intervention portfolio | Distribution depth in ambulatory channel |
| Terumo Corporation | ~4–6% | Interventional access and support systems | Asia-Pacific incumbency; Japan reimbursement fluency |
| AngioDynamics, Inc. | ~3–5% | Mechanical debulking and thrombus management | Focused peripheral specialist |
| Avinger, Inc. | ~1–3% | Image-guided catheter platforms | OCT-integrated niche differentiation |
| Rex Medical, L.P. | ~1–3% | Peripheral debulking devices | Litigation-tested IP; partner-led commercialization |
| Straub Medical AG | ~1–2% | Rotational thrombectomy systems | European specialist; BD-aligned distribution |

## Recent News & Developments

## Recent News & Developments

- Abbott (April 2023): Completed its USD 890 million acquisition of Cardiovascular Systems Inc., adding orbital platforms to its vascular portfolio and reshaping share dynamics [[16]](https://abbott.com).
- U.S. FDA (September 2023): Cleared an expanded indication for a peripheral debulking catheter in below-the-knee anatomy, opening a previously label-restricted patient pool [[17]](https://fda.gov).
- Philips (March 2024): Launched a next-generation laser console with integrated imaging co-registration, targeting in-stent restenosis workflows [[26]](https://philips.com).
- Boston Scientific (June 2024): Announced a multi-year supply agreement with a U.S. ambulatory surgery network covering vessel preparation devices [[27]](https://bostonscientific.com).
- HHS Office of Inspector General (July 2024): Added office-based peripheral intervention utilization to its active work plan, signaling audit exposure for high-volume operators [[6]](https://oig.hhs.gov).
- Terumo (November 2024): Opened an expanded interventional device manufacturing line in the Philippines to serve Asia-Pacific demand [[28]](https://terumo.com).
- European Commission (January 2025): Extended selected MDR transition timelines for legacy Class III devices, easing near-term recertification pressure on smaller suppliers [[8]](https://health.ec.europa.eu).
- Medtronic (May 2025): Initiated a post-market registry evaluating debulking plus drug-coated balloon sequencing across 40 European centres [[29]](https://medtronic.com).

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global atherectomy device revenue across coronary, peripheral, and neurovascular applications |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 7.0% (2026–2035) |
| Market Size Checkpoints | USD 1.14 Billion (2025); USD 1.22 Billion (2026); USD 2.24 Billion (2035) |
| Fastest Growing Segments | Orbital systems (product); Ambulatory care centers (end user); Asia-Pacific (region) |
| Companies Profiled | 11 major suppliers to the Atherectomy Devices Market |
| Valuation Currency | USD, manufacturer selling price basis |

## Frequently Asked Questions

**Q: What should procurement teams evaluate first when entering the Atherectomy Devices Market as buyers?**
A: Total cost per completed case, not list price. Embolic protection filters, wires, and extended procedure time frequently add 30–45% to the headline device cost [15].

**Q: How does operator training availability affect adoption timelines?**
A: Proctored case requirements typically span 8–15 procedures before independent use. Centres without proctor access often delay launch by two or three quarters [9].

**Q: Do hospital group purchasing organizations constrain access to the Atherectomy Devices Market?**
A: Yes, materially. GPO contracts frequently lock device categories for 24–36 months, and off-contract purchases require value-analysis committee override [14].

**Q: What integration challenges arise with existing cath lab equipment?**
A: Console footprint and power requirements matter most in older labs. Some platforms also require specific guidewire compatibility, which fragments inventory management [26].

**Q: Which regulatory nuance most affects new entrants to the Atherectomy Devices Market?**
A: Clinical evidence expectations differ sharply. European MDR now demands device-specific clinical data where equivalence claims previously sufficed, adding 12–18 months to launch timelines [8].

**Q: How are investors valuing pure-play suppliers in this space?**
A: Revenue multiples compressed after 2023 consolidation. Buyers now price reimbursement durability and installed base over growth rate alone [16].

**Q: Where are the most credible emerging use cases?**
A: Venous applications and dialysis access maintenance show early promise. Both involve fibrotic obstruction that responds to mechanical debulking [29].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/atherectomy-devices-market-7322*